John Hyngstrom

Associate Professor, Surgical Oncology

Rush University Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose: We report results from two clinical trials of the cyclic dinucleotide stimulator of IFN genes (STING) agonist ulevostinag. Patients and Methods: In a phase I study (NCT03010176) with an accelerated titration design/modified toxicity probability interval method, participants with advanced/metastatic solid tumors or lymphomas received intratumoral ulevostinag (±intravenous pembrolizumab). In an expansion phase, participants with head and neck squamous cell carcinoma (HNSCC) or triple-negative breast cancer received the combination. Primary objectives were safety/tolerability and identifying the recommended phase II dose; biomarkers were exploratory. In a randomized phase II study (NCT04220866), participants with untreated metastatic or unresectable, recurrent HNSCC received intravenous pembrolizumab (±ulevostinag 540 µg). The primary objective was antitumor activity. Pembrolizumab 200 mg was administered every 3 weeks in both studies. Results: In the phase I study (NCT03010176; N = 156), the most common adverse event was pyrexia (70%). Plasma ulevostinag concentrations increased dose-dependently. Circulating levels of C-X-C motif chemokine 10, IFNγ, and IL-6 showed elevation at 2 to 4 hours, peak at 6 to 8 hours, and plateau/partial resolution at 24 hours but, beyond the 540 µg dose, did not show a clear dose–effect relationship. Ten participants experienced dose-limiting toxicities; the recommended phase II dose for intratumoral ulevostinag was 540 µg. In the phase II study (NCT04220866), 4 of 8 participants treated with combination therapy and 1 of 10 treated with pembrolizumab monotherapy had a complete or partial response. The most common adverse event was pyrexia ( n = 5). Conclusions: Intratumoral ulevostinag (±pembrolizumab) had manageable toxicity, dose-dependent pharmacokinetics, and evidence of STING activation and target engagement. Combination therapy showed antitumor activity in participants with untreated metastatic or unresectable, recurrent HNSCC.

Year:

2025

Supplementary Figure S1. Study design for Study 1. In Arm 1 (part A), treatment with IT ulevostinag began at 10 μg, with dose escalation proceeding based on safety events to a maximum dose of 3000 μg.

Year:

2025

Background Tattooing can deliver carcinogens directly into the skin and cause immunologic responses, yet the relationship between tattooing and melanoma risk is unknown. Methods In a population-based case-control study with 1,167 melanoma cases (566 in situ; 601 invasive) and 5,835 frequency-matched controls, we examined tattooing and melanoma risk using multivariable logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results While ever receiving a tattoo was not strongly associated with melanoma risk, heavier tattooing exposure was associated with decreased risk. Melanoma risk was decreased among individuals who had received four or more tattoo sessions (OR 0·44 [95% CI 0·27–0·67]) and individuals who had three or more large tattoos (OR 0·26 [95% CI 0·10–0·54) compared with those who were never tattooed. Invasive melanoma risk was decreased among individuals who received their first tattoo before age 20 (OR 0·48 [95% CI 0·29–0·82]) compared with never tattooed individuals. These patterns were stronger among men than women. Conversely, individuals who had only received one tattoo session had a higher risk of melanoma (OR 1·53 [95% CI 1·16–2·00) compared with individuals who were never tattooed, particularly for in situ melanoma (OR 1·85 [95% CI 1·31–2·63). Conclusions Our findings suggest a complex relationship between tattooing and melanoma risk. There was evidence of reduced melanoma risk with more tattoo exposure, but also increased risk among those who were only tattooed once. The potential causes of these seemingly contradictory associations could include a variety of factors including sun exposure-related behaviors or immune responses to timing and quantities of tattooing. These findings justify further investigation.

Year:

2025

Acral melanoma (AM) is an aggressive melanoma variant that arises from palmar, plantar, and nail unit melanocytes. Compared to non-acral cutaneous melanoma (CM), AM is biologically distinct, has an equal incidence across genetic ancestries, typically presents in advanced stage disease, is less responsive to therapy, and has an overall worse prognosis. Independent analysis of published genomic and transcriptomic sequencing identified that receptor tyrosine kinase (RTK) ligands and adapter proteins are frequently amplified, translocated, and/or overexpressed in AM. To target these unique genetic changes, a zebrafish acral melanoma model was exposed to a panel of narrow and broad spectrum multi-RTK inhibitors, revealing that dual FGFR/VEGFR inhibitors decrease acral-analogous melanocyte proliferation and migration. The potent pan-FGFR/VEGFR inhibitor, Lenvatinib, uniformly induces tumor regression in AM patient-derived xenograft (PDX) tumors but only slows tumor growth in CM models. Unlike other multi-RTK inhibitors, Lenvatinib is not directly cytotoxic to dissociated AM PDX tumor cells and instead disrupts tumor architecture and vascular networks. Considering the great difficulty in establishing AM cell culture lines, these findings suggest that AM may be more sensitive to microenvironment perturbations than CM. In conclusion, dual FGFR/VEGFR inhibition may be a viable therapeutic strategy that targets the unique biology of AM.

Year:

2024

Collaborators (19)

Emanuela Romano

PSL Research University

FRANCE
View details

Amanda Jiang

Huntsman Cancer Institute

UNITED STATES
View details

Britton Trabert

Associate Professor

University of Utah

UNITED STATES
View details

Rachel Belote

Assistant Professor

Ohio State University

UNITED STATES
View details

Richard White

Professor

University of Oxford

UNITED KINGDOM
View details

Talia Golan

-

ISRAEL
View details

Dekker Deacon

Assistant Professor

University of Utah

UNITED STATES
View details

Morgan Millar

University of Utah

UNITED STATES
View details

Lindsay J Collin

Assistant Professor

Emory University

UNITED STATES
View details

Byoung Chul Cho

PI/Professor

-

SOUTH KOREA
View details

Joshua Brody

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Douglas Grossman

Professor

University of Utah Health Sciences Center

UNITED STATES
View details

Kevin Harrington

Head of Division of Radiotherapy and Imaging

Institute of Cancer Research

UNITED KINGDOM
View details

Robert Judson‐Torres

-

UNITED STATES
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Thomas Zangle

Associate Professor

University of Utah

UNITED STATES
View details

Sung-Bae Kim

University of Ulsan College of Medicine

SOUTH KOREA
View details

Nelly Cruz

Senior Research Scientist

Sloan Kettering Institute

UNITED STATES
View details

Matthew Ingham

Columbia University Irving Medical Center

UNITED STATES
View details